
ICON Public Limited Company (NASDAQ: ICLR) Stock Competitors & Peer Comparison
See ICLR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ICLR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ICLR | $191.40 | -1.67% | 14.3B | 15.61 | $12.26 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $691.33 | -1.27% | 256.3B | 29.87 | $23.16 | +0.27% |
| DHR | $229.91 | -1.33% | 161.9B | 28.84 | $7.98 | +0.66% |
| IDXX | $700.65 | -0.51% | 55.2B | 49.27 | $14.22 | N/A |
| A | $172.92 | -0.60% | 48.8B | 29.78 | $5.81 | +0.59% |
| WAT | $453.42 | -1.48% | 44.6B | 33.15 | $13.68 | N/A |
| IQV | $264.73 | -0.15% | 43.6B | 21.82 | $12.13 | N/A |
| NTRA | $288.48 | -9.59% | 41.8B | -218.55 | -$1.32 | N/A |
| MTD | $1,727.26 | -0.67% | 34.4B | 39.74 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
ICLR vs DHR-PB Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, ICLR's ROE is +0.05%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, ICLR is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
ICLR vs TMO Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, TMO has a market cap of 256.3B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while TMO trades at $691.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas TMO's P/E ratio is 29.87. In terms of profitability, ICLR's ROE is +0.05%, compared to TMO's ROE of +0.13%. Regarding short-term risk, ICLR is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
ICLR vs DHR Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, DHR has a market cap of 161.9B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while DHR trades at $229.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas DHR's P/E ratio is 28.84. In terms of profitability, ICLR's ROE is +0.05%, compared to DHR's ROE of +0.08%. Regarding short-term risk, ICLR is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
ICLR vs IDXX Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, IDXX has a market cap of 55.2B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while IDXX trades at $700.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas IDXX's P/E ratio is 49.27. In terms of profitability, ICLR's ROE is +0.05%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, ICLR is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
ICLR vs A Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, A has a market cap of 48.8B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while A trades at $172.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas A's P/E ratio is 29.78. In terms of profitability, ICLR's ROE is +0.05%, compared to A's ROE of +0.20%. Regarding short-term risk, ICLR is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check A's competition here
Waters Corporation (NYSE: WAT)
ICLR vs WAT Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, WAT has a market cap of 44.6B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while WAT trades at $453.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas WAT's P/E ratio is 33.15. In terms of profitability, ICLR's ROE is +0.05%, compared to WAT's ROE of +0.01%. Regarding short-term risk, ICLR is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
ICLR vs IQV Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, IQV has a market cap of 43.6B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while IQV trades at $264.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas IQV's P/E ratio is 21.82. In terms of profitability, ICLR's ROE is +0.05%, compared to IQV's ROE of +0.22%. Regarding short-term risk, ICLR is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
ICLR vs NTRA Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, NTRA has a market cap of 41.8B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while NTRA trades at $288.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas NTRA's P/E ratio is -218.55. In terms of profitability, ICLR's ROE is +0.05%, compared to NTRA's ROE of -0.09%. Regarding short-term risk, ICLR is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check NTRA's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
ICLR vs MTD Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, MTD has a market cap of 34.4B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while MTD trades at $1,727.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas MTD's P/E ratio is 39.74. In terms of profitability, ICLR's ROE is +0.05%, compared to MTD's ROE of +149.66%. Regarding short-term risk, ICLR is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
ICLR vs LH Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, LH has a market cap of 30.3B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while LH trades at $372.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas LH's P/E ratio is 22.11. In terms of profitability, ICLR's ROE is +0.05%, compared to LH's ROE of +0.12%. Regarding short-term risk, ICLR is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check LH's competition here
Illumina, Inc. (NASDAQ: ILMN)
ICLR vs ILMN Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, ILMN has a market cap of 29.9B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while ILMN trades at $198.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas ILMN's P/E ratio is 39.36. In terms of profitability, ICLR's ROE is +0.05%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, ICLR is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check ILMN's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
ICLR vs DGX Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, DGX has a market cap of 28.9B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while DGX trades at $262.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas DGX's P/E ratio is 25.87. In terms of profitability, ICLR's ROE is +0.05%, compared to DGX's ROE of +0.15%. Regarding short-term risk, ICLR is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check DGX's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
ICLR vs EXAS Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas EXAS's P/E ratio is -95.37. In terms of profitability, ICLR's ROE is +0.05%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, ICLR is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check EXAS's competition here
Guardant Health, Inc. (NASDAQ: GH)
ICLR vs GH Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, GH has a market cap of 19.5B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while GH trades at $144.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas GH's P/E ratio is -41.27. In terms of profitability, ICLR's ROE is +0.05%, compared to GH's ROE of +2.49%. Regarding short-term risk, ICLR is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check GH's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
ICLR vs MEDP Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, MEDP has a market cap of 18.1B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while MEDP trades at $648.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas MEDP's P/E ratio is 35.93. In terms of profitability, ICLR's ROE is +0.05%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, ICLR is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
ICLR vs ILMNV Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas ILMNV's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.05%, compared to ILMNV's ROE of N/A. Regarding short-term risk, ICLR is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
ICLR vs RVTY Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, RVTY has a market cap of 16.6B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while RVTY trades at $148.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas RVTY's P/E ratio is 27.84. In terms of profitability, ICLR's ROE is +0.05%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, ICLR is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check RVTY's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
ICLR vs CRL Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, CRL has a market cap of 16.2B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while CRL trades at $335.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas CRL's P/E ratio is 34.14. In terms of profitability, ICLR's ROE is +0.05%, compared to CRL's ROE of +0.01%. Regarding short-term risk, ICLR is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
ICLR vs PKI Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas PKI's P/E ratio is 41.45. In terms of profitability, ICLR's ROE is +0.05%, compared to PKI's ROE of +0.04%. Regarding short-term risk, ICLR is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check PKI's competition here
Qiagen N.V. (NYSE: QGEN)
ICLR vs QGEN Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, QGEN has a market cap of 10.3B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while QGEN trades at $49.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas QGEN's P/E ratio is 20.58. In terms of profitability, ICLR's ROE is +0.05%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, ICLR is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
ICLR vs RDNT Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while RDNT trades at $76.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas RDNT's P/E ratio is 167.15. In terms of profitability, ICLR's ROE is +0.05%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, ICLR is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
ICLR vs GRAL Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, GRAL has a market cap of 4.7B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while GRAL trades at $105.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas GRAL's P/E ratio is -10.83. In terms of profitability, ICLR's ROE is +0.05%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, ICLR is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check GRAL's competition here
Sotera Health Company (NASDAQ: SHC)
ICLR vs SHC Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, SHC has a market cap of 4.6B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while SHC trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas SHC's P/E ratio is 16.93. In terms of profitability, ICLR's ROE is +0.05%, compared to SHC's ROE of +0.26%. Regarding short-term risk, ICLR is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
ICLR vs BLLN Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, BLLN has a market cap of 4.6B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while BLLN trades at $96.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas BLLN's P/E ratio is 137.59. In terms of profitability, ICLR's ROE is +0.05%, compared to BLLN's ROE of +0.09%. Regarding short-term risk, ICLR is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
ICLR vs SYNH Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas SYNH's P/E ratio is 61.40. In terms of profitability, ICLR's ROE is +0.05%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, ICLR is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
ICLR vs CDNA Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, CDNA has a market cap of 4.1B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while CDNA trades at $73.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas CDNA's P/E ratio is 92.71. In terms of profitability, ICLR's ROE is +0.05%, compared to CDNA's ROE of +0.34%. Regarding short-term risk, ICLR is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
ICLR vs OLK Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas OLK's P/E ratio is -96.59. In terms of profitability, ICLR's ROE is +0.05%, compared to OLK's ROE of -0.07%. Regarding short-term risk, ICLR is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
ICLR vs NEO Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, NEO has a market cap of 2B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while NEO trades at $15.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas NEO's P/E ratio is 118.54. In terms of profitability, ICLR's ROE is +0.05%, compared to NEO's ROE of -0.04%. Regarding short-term risk, ICLR is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check NEO's competition here
Veracyte, Inc. (NASDAQ: VCYT)
ICLR vs VCYT Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, VCYT has a market cap of 1.9B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while VCYT trades at $24.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas VCYT's P/E ratio is 12.01. In terms of profitability, ICLR's ROE is +0.05%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, ICLR is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check VCYT's competition here
Personalis, Inc. (NASDAQ: PSNL)
ICLR vs PSNL Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, PSNL has a market cap of 1.6B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while PSNL trades at $14.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas PSNL's P/E ratio is -13.58. In terms of profitability, ICLR's ROE is +0.05%, compared to PSNL's ROE of -0.50%. Regarding short-term risk, ICLR is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check PSNL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
ICLR vs WGS Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, WGS has a market cap of 1.5B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while WGS trades at $51.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas WGS's P/E ratio is 141.72. In terms of profitability, ICLR's ROE is +0.05%, compared to WGS's ROE of -0.42%. Regarding short-term risk, ICLR is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check WGS's competition here
OPKO Health, Inc. (NASDAQ: OPK)
ICLR vs OPK Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while OPK trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas OPK's P/E ratio is -18.00. In terms of profitability, ICLR's ROE is +0.05%, compared to OPK's ROE of -0.12%. Regarding short-term risk, ICLR is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
ICLR vs CSTL Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while CSTL trades at $32.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas CSTL's P/E ratio is -51.20. In terms of profitability, ICLR's ROE is +0.05%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, ICLR is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
ICLR vs FLGT Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, FLGT has a market cap of 672.6M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while FLGT trades at $24.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas FLGT's P/E ratio is 2407.50. In terms of profitability, ICLR's ROE is +0.05%, compared to FLGT's ROE of -0.09%. Regarding short-term risk, ICLR is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
ICLR vs GRALV Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas GRALV's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.05%, compared to GRALV's ROE of N/A. Regarding short-term risk, ICLR is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
ICLR vs MYGN Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, MYGN has a market cap of 534.3M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while MYGN trades at $5.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas MYGN's P/E ratio is -42.85. In terms of profitability, ICLR's ROE is +0.05%, compared to MYGN's ROE of -0.40%. Regarding short-term risk, ICLR is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
ICLR vs CO Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas CO's P/E ratio is 5.06. In terms of profitability, ICLR's ROE is +0.05%, compared to CO's ROE of +0.11%. Regarding short-term risk, ICLR is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
ICLR vs FLDM Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas FLDM's P/E ratio is -4.74. In terms of profitability, ICLR's ROE is +0.05%, compared to FLDM's ROE of +0.26%. Regarding short-term risk, ICLR is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check FLDM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
ICLR vs GTH Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas GTH's P/E ratio is -1.11. In terms of profitability, ICLR's ROE is +0.05%, compared to GTH's ROE of -1.01%. Regarding short-term risk, ICLR is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
ICLR vs GENE Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas GENE's P/E ratio is -38.25. In terms of profitability, ICLR's ROE is +0.05%, compared to GENE's ROE of -1.85%. Regarding short-term risk, ICLR is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check GENE's competition here
Exagen Inc. (NASDAQ: XGN)
ICLR vs XGN Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, XGN has a market cap of 96.2M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while XGN trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas XGN's P/E ratio is -4.65. In terms of profitability, ICLR's ROE is +0.05%, compared to XGN's ROE of -1.26%. Regarding short-term risk, ICLR is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
ICLR vs FRNM Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, FRNM has a market cap of 82.3M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while FRNM trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas FRNM's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.05%, compared to FRNM's ROE of -0.60%. Regarding short-term risk, ICLR is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check FRNM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
ICLR vs BDSX Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, BDSX has a market cap of 73.3M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while BDSX trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas BDSX's P/E ratio is -2.84. In terms of profitability, ICLR's ROE is +0.05%, compared to BDSX's ROE of -4.42%. Regarding short-term risk, ICLR is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check BDSX's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
ICLR vs IMDX Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, IMDX has a market cap of 60.9M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while IMDX trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas IMDX's P/E ratio is -1.25. In terms of profitability, ICLR's ROE is +0.05%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, ICLR is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
ICLR vs PRPO Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, PRPO has a market cap of 35.8M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while PRPO trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas PRPO's P/E ratio is -30.71. In terms of profitability, ICLR's ROE is +0.05%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, ICLR is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
ICLR vs AKU Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas AKU's P/E ratio is -0.13. In terms of profitability, ICLR's ROE is +0.05%, compared to AKU's ROE of -5.32%. Regarding short-term risk, ICLR is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
ICLR vs CEMI Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas CEMI's P/E ratio is -0.63. In terms of profitability, ICLR's ROE is +0.05%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, ICLR is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
ICLR vs ENZ Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas ENZ's P/E ratio is -2.24. In terms of profitability, ICLR's ROE is +0.05%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, ICLR is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
ICLR vs PMD Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas PMD's P/E ratio is -5.24. In terms of profitability, ICLR's ROE is +0.05%, compared to PMD's ROE of -0.32%. Regarding short-term risk, ICLR is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
ICLR vs ME Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas ME's P/E ratio is -0.03. In terms of profitability, ICLR's ROE is +0.05%, compared to ME's ROE of -3.47%. Regarding short-term risk, ICLR is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
ICLR vs MYNZ Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, ICLR's ROE is +0.05%, compared to MYNZ's ROE of -0.90%. Regarding short-term risk, ICLR is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check MYNZ's competition here
MDxHealth S.A. (NASDAQ: MDXH)
ICLR vs MDXH Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, MDXH has a market cap of 14.7M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while MDXH trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas MDXH's P/E ratio is -0.21. In terms of profitability, ICLR's ROE is +0.05%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, ICLR is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check MDXH's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
ICLR vs BNR Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, BNR has a market cap of 14M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while BNR trades at $12.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas BNR's P/E ratio is -14.64. In terms of profitability, ICLR's ROE is +0.05%, compared to BNR's ROE of -0.13%. Regarding short-term risk, ICLR is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check BNR's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
ICLR vs QUCY Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, QUCY has a market cap of 13.5M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while QUCY trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas QUCY's P/E ratio is -0.03. In terms of profitability, ICLR's ROE is +0.05%, compared to QUCY's ROE of -2.44%. Regarding short-term risk, ICLR is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check QUCY's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
ICLR vs BIAF Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, BIAF has a market cap of 12.6M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while BIAF trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas BIAF's P/E ratio is -0.23. In terms of profitability, ICLR's ROE is +0.05%, compared to BIAF's ROE of -3.31%. Regarding short-term risk, ICLR is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check BIAF's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
ICLR vs CHEK Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas CHEK's P/E ratio is -0.43. In terms of profitability, ICLR's ROE is +0.05%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, ICLR is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
ICLR vs CNTG Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas CNTG's P/E ratio is -0.23. In terms of profitability, ICLR's ROE is +0.05%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, ICLR is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
ICLR vs APDN Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas APDN's P/E ratio is -0.10. In terms of profitability, ICLR's ROE is +0.05%, compared to APDN's ROE of -5.84%. Regarding short-term risk, ICLR is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
ICLR vs NDRA Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, NDRA has a market cap of 6.6M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while NDRA trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas NDRA's P/E ratio is -0.66. In terms of profitability, ICLR's ROE is +0.05%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, ICLR is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
ICLR vs NVTA Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas NVTA's P/E ratio is -0.00. In terms of profitability, ICLR's ROE is +0.05%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, ICLR is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check NVTA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
ICLR vs BIAFW Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, BIAFW has a market cap of 5.4M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while BIAFW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas BIAFW's P/E ratio is 0.57. In terms of profitability, ICLR's ROE is +0.05%, compared to BIAFW's ROE of -3.31%. Regarding short-term risk, ICLR is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check BIAFW's competition here
LumiraDx Limited (NASDAQ: LMDX)
ICLR vs LMDX Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas LMDX's P/E ratio is -0.01. In terms of profitability, ICLR's ROE is +0.05%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, ICLR is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
ICLR vs LMDXW Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, ICLR's ROE is +0.05%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, ICLR is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check LMDXW's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
ICLR vs ADVB Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, ADVB has a market cap of 3.7M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while ADVB trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas ADVB's P/E ratio is -20.18. In terms of profitability, ICLR's ROE is +0.05%, compared to ADVB's ROE of +0.58%. Regarding short-term risk, ICLR is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
ICLR vs DMTK Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas DMTK's P/E ratio is -0.04. In terms of profitability, ICLR's ROE is +0.05%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, ICLR is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
ICLR vs NOTV Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas NOTV's P/E ratio is -0.03. In terms of profitability, ICLR's ROE is +0.05%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, ICLR is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
ICLR vs SQL Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas SQL's P/E ratio is -0.40. In terms of profitability, ICLR's ROE is +0.05%, compared to SQL's ROE of -30.46%. Regarding short-term risk, ICLR is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
ICLR vs AWH Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas AWH's P/E ratio is -0.09. In terms of profitability, ICLR's ROE is +0.05%, compared to AWH's ROE of +1.62%. Regarding short-term risk, ICLR is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
ICLR vs ISPC Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, ISPC has a market cap of 1.5M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while ISPC trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas ISPC's P/E ratio is -0.02. In terms of profitability, ICLR's ROE is +0.05%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, ICLR is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
ICLR vs HTGM Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas HTGM's P/E ratio is -0.03. In terms of profitability, ICLR's ROE is +0.05%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, ICLR is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
ICLR vs BIOC Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas BIOC's P/E ratio is -0.01. In terms of profitability, ICLR's ROE is +0.05%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, ICLR is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
ICLR vs SQLLW Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, ICLR's ROE is +0.05%, compared to SQLLW's ROE of +22.06%. Regarding short-term risk, ICLR is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
ICLR vs WGSWW Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, ICLR's ROE is +0.05%, compared to WGSWW's ROE of -0.42%. Regarding short-term risk, ICLR is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
ICLR vs BNGOW Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas BNGOW's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.05%, compared to BNGOW's ROE of -0.85%. Regarding short-term risk, ICLR is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check BNGOW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
ICLR vs MEUSW Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas MEUSW's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.05%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, ICLR is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
ICLR vs PRXL Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas PRXL's P/E ratio is 42.97. In terms of profitability, ICLR's ROE is +0.05%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, ICLR is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check PRXL's competition here
Danaher Corporation (NYSE: DHR-PA)
ICLR vs DHR-PA Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, ICLR's ROE is +0.05%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, ICLR is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check DHR-PA's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
ICLR vs NDRAW Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas NDRAW's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.05%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, ICLR is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
ICLR vs CHEKZ Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.05%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, ICLR is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for ICLR.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
ICLR vs OCDX Comparison November 2026
ICON Public Limited Company (NASDAQ: ICLR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 14.3B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, ICLR is priced at $191.40 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 15.61, whereas OCDX's P/E ratio is -42.28. In terms of profitability, ICLR's ROE is +0.05%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, ICLR is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for ICLR.Check OCDX's competition here